Edition:
United States

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.26USD
23 May 2018
Change (% chg)

$-0.00 (-0.66%)
Prev Close
$0.26
Open
$0.27
Day's High
$0.28
Day's Low
$0.26
Volume
152,745
Avg. Vol
264,789
52-wk High
$1.63
52-wk Low
$0.24

Latest Key Developments (Source: Significant Developments)

Trovagene Announces Activation Of Second Clinical Trial Site In Phase 1B/2 Acute Myeloid Leukemia Trial
Thursday, 21 Dec 2017 08:00am EST 

Dec 21 (Reuters) - Trovagene Inc ::TROVAGENE ANNOUNCES ACTIVATION OF SECOND CLINICAL TRIAL SITE IN PHASE 1B/2 ACUTE MYELOID LEUKEMIA (AML) TRIAL FOR PCM-075.TROVAGENE INC - ACTIVATION OF SECOND CLINICAL TRIAL SITE FOR ITS PHASE 1B/2 MULTICENTER TRIAL OF PCM-075 IN PATIENTS WITH AML.  Full Article

Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of Pcm-075 In Combination With Zytiga®
Thursday, 14 Dec 2017 08:00am EST 

Dec 14 (Reuters) - Trovagene Inc ::TROVAGENE SUBMITS PROTOCOL TO FDA FOR PHASE 2 CLINICAL TRIAL OF PCM-075 IN COMBINATION WITH ZYTIGA® FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.TROVAGENE INC - ‍LOOKING FORWARD TO A DECISION FROM FDA PERMITTING STUDY TO PROCEED, INITIATING MCRPC CLINICAL TRIAL IN PROSTATE CANCER IN 2018​.  Full Article

Trovagene Inc updates on clinical trial for PCM-075
Monday, 13 Nov 2017 08:00am EST 

Nov 13 (Reuters) - Trovagene Inc ::Trovagene announces activation of first clinical trial site in phase 1B/2 acute myeloid leukemia (AML) trial for PCM-075.Trovagene Inc - ‍activation of its clinical trial site for its phase 1B/2 multicenter trial of PCM-075 in patients with AML​.Trovagene Inc - ‍trial will enroll subjects in phase 1B who have relapsed or have resistant disease to no more than three prior regimens​.  Full Article

TROVAGENE REPORTS Q3 LOSS PER SHARE $0.12
Thursday, 9 Nov 2017 10:18am EST 

Nov 9 (Reuters) - Trovagene Inc ::Q3 LOSS PER SHARE $0.12.‍AS OF SEPTEMBER 30, 2017, TROVAGENE HAD APPROXIMATELY $7.4 MILLION OF CASH AND CASH EQUIVALENTS​.  Full Article

Trovagene files for offering of up to $17.5 mln- SEC filing
Wednesday, 25 Oct 2017 05:01pm EDT 

Oct 25 (Reuters) - Trovagene Inc : :Trovagene Inc files for offering of up to $17.5 million - SEC filing.  Full Article

Fda grants orphan drug designation to Trovagene's PLK1 inhibitor, PCM-075
Monday, 9 Oct 2017 08:00am EDT 

Oct 9 (Reuters) - Trovagene Inc :Fda grants orphan drug designation to trovagene's PLK1 inhibitor, PCM-075, for the treatment of acute myeloid leukemia (AML).Trovagene - initiating Phase 1b/2 open-label trial to evaluate safety & anti-leukemic activity of PCM-075 in combination with standard-of-care in patients with AML​.  Full Article

Trovagene reports Q2 loss per share $0.34
Thursday, 4 Aug 2016 04:15pm EDT 

Trovagene Inc : Q2 loss per share $0.34 . Trovagene reports second quarter 2016 financial results and accomplishments .Q2 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.  Full Article

Trovagene entered into Fifth amendment to loan and security agreement with Oxford Finance, Silicon Valley Bank
Tuesday, 26 Jul 2016 04:32pm EDT 

Trovagene Inc : On July 20, 2016, Co entered into Fifth amendment to loan and security agreement with Oxford Finance LLC, Silicon Valley Bank .Maturity date of loan was amended to february 1, 2020 - sec filing.  Full Article

BRIEF-Trovagene Completes First Dosing Cohort Of Patients In Phase 1B/2 Trial Of PCM-075

* TROVAGENE ANNOUNCES COMPLETION OF FIRST DOSING COHORT OF PATIENTS IN ONGOING PHASE 1B/2 TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage: